- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00003669
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer
Phase II Nonrandomized Study of LY353381-HC1 in Patients With Recurrent or Advanced Endometrial Cancer
RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using arzoxifene hydrochloride may fight the endometrial cancer by blocking the use of estrogen by the tumor cells
PURPOSE: This phase II trial is studying how well arzoxifene hydrochloride works in treating women with recurrent, advanced, or metastatic endometrial cancer.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES: I. Determine the objective tumor response rate (complete response and partial response) to arzoxifene hydrochloride in patients with recurrent or advanced endometrial cancer. II. Determine the time to progressive disease, time to treatment failure, response duration, and survival in patients with recurrent or advanced endometrial cancer receiving arzoxifene hydrochloride. III. Assess the safety of this treatment in these patients. IV. Measure changes in serum estradiol, follicle stimulating hormone, luteinizing hormone, and sex hormone binding globulin during this treatment in these patients.
OUTLINE: Patients receive oral arzoxifene hydrochloride daily at a fixed dose. Treatment continues in the absence of unacceptable toxicity or disease progression.
PROJECTED ACCRUAL: Not specified
National Cancer Institute (NCI) registered this trial with Eli Lilly as sponsor. NCI did not update the record when the trial completed. In June 2012, NCI transferred the trial to Lilly's clinicaltrials.gov account and Lilly updated the record with the trial completion date. This trial is not an applicable trial under Food and Drug Administration Amendments Act of 2007 (FDAAA).
Studientyp
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
California
-
Pasadena, California, Vereinigte Staaten, 91109-7013
- Huntington Memorial Hospital
-
-
Missouri
-
Columbia, Missouri, Vereinigte Staaten, 65203
- Ellis Fischel Cancer Center - Columbia
-
Saint Louis, Missouri, Vereinigte Staaten, 63110
- Washington University Barnard Cancer Center
-
-
New York
-
New York, New York, Vereinigte Staaten, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599-7295
- Lineberger Comprehensive Cancer Center, UNC
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Arthur G. James Cancer Hospital - Ohio State University
-
Columbus, Ohio, Vereinigte Staaten, 43214
- Grant/Riverside Methodist Hospitals
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73190
- University of Oklahoma Health Sciences Center
-
-
Pennsylvania
-
Abington, Pennsylvania, Vereinigte Staaten, 19001
- Abington Memorial Hospital
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77060
- U.S. Oncology
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS: Histologically confirmed recurrent, advanced, or metastatic endometrial cancer not amenable to curative surgery or radiotherapy Patients should have previously undergone radical surgery (minimum of total abdominal hysterectomy and bisalpingoophorectomy), radical radiotherapy, or not be candidate for such procedures Bidimensionally measurable disease by x-ray, CT scan, MRI, or physical exam No papillary serous or clear cell carcinomas of the endometrium Hormone receptor status: Estrogen receptor positive and/or progesterone receptor positive Unknown receptor status patients allowed provided (1) original tumor was well- or moderately-well differentiated (2) had endometrioid histology
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Menopausal status: Not specified Life expectancy: At least 12 weeks Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9 g/dL (transfusion-independent) Prothrombin time or activated partial thromboplastin time no greater than 1.25 times upper limit of normal (ULN) Hepatic: Bilirubin no greater than 1.5 times normal ALT or AST no greater than 2.5 times ULN (ALT and AST no greater than 5 times ULN in the presence of liver metastases) Renal: Creatinine no greater than 1.5 ULN Other: No other primary malignancy within the past 5 years except adequately treated nonmelanomatous cancer of the skin or carcinoma in situ of the cervix
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy for recurrent or metastatic endometrial cancer At least 1 year since prior adjuvant chemotherapy Endocrine therapy: No prior antiestrogen therapy for any stage of endometrial cancer At least 12 months from time of diagnosis since prior raloxifene Prior progesterone treatment allowed Radiotherapy: See Disease Characteristics At least 2 weeks since prior radiotherapy and recovered Surgery: See Disease Characteristics
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2141
- LILLY-H4Z-MC-JWWI
- MSKCC-99001
- CDR0000066766
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Arzoxifenhydrochlorid
-
M.D. Anderson Cancer CenterZurückgezogenMetastasierendes nicht-kleinzelliges Lungenkarzinom | Lungenkrebs im Stadium IVA AJCC v8 | Lungenkrebs im Stadium IVB AJCC v8 | Lungenkrebs im Stadium IV AJCC v8
-
Betta Pharmaceuticals Co., Ltd.Tigermed Consulting Co., LtdAbgeschlossenSchuppenflechteChina
-
Zhejiang UniversityHuashan Hospital; West China Hospital; The First Affiliated Hospital of Zhengzhou... und andere MitarbeiterBeendet
-
AVEO Pharmaceuticals, Inc.AbgeschlossenLeberfunktionsstörungVereinigte Staaten
-
LanZhou UniversityGeneral Hospital of Ningxia Medical UniversityUnbekanntFortgeschrittenes nicht-plattenepitheliales NSCLC
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Unbekannt
-
Peking Union Medical College HospitalRekrutierungPhäochromozytom | ParagangliomChina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdNoch keine RekrutierungNeuartige COVID-19-infizierte LungenentzündungChina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdAbgeschlossen
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdAbgeschlossen